UK MHRA: ‘At Least Half’ Of Novel Drug Filings To Take National Assessment Route

 
• By Ian Schofield

With approval applications for new active substances expected to rise by 25% by 2026, the UK regulator says it wants to focus its national assessment procedure on new innovative therapies. It will also review progress with the new International Recognition Procedure.

Innovation light bulb
The MHRA is expecting a rise in filings for innovative drugs (Shutterstock)

More from Agency Leadership

More from Pathways & Standards